Samsung Biologics to attend 2025 BIO International Convention

Samsung Biologics will be attending the 2025 BIO International Convention in Boston between June 16-19 this year.

Stop by Booth #565 to hear how our expanded capabilities and advanced platform technologies can support your program's success. From monoclonal antibodies (mAbs) and recombinant proteins to complex modalities such as mRNAs, multispecifics, and antibody-drug conjugates (ADCs), our team is ready to support your program's accelerated path to the next milestone.

The company opened the latest Plant 5 early this year to launch its second Bio Campus, bringing total combined capacity up to 784 kL. With the recent launch of our dedicated ADC facility and our fully integrated, end-to-end offerings, we are uniquely positioned to streamline development and manufacturing.

Samsung Biologics will also showcase its competitive strengths in seamless end-to-end CDMO capabilities to support diverse and complex molecules. In the booth, AI-powered operations and digital transformation to optimize bioprocesses will also be featured.

Meetings with existing and potential clients will take place throughout the event to support them in achieving development and manufacturing milestones.

Samsung Biologics will be attending the 2025 BIO International Convention in Boston between June 16-19 this year.

Stop by Booth #565 to hear how our expanded capabilities and advanced platform technologies can support your program's success. From monoclonal antibodies (mAbs) and recombinant proteins to complex modalities such as mRNAs, multispecifics, and antibody-drug conjugates (ADCs), our team is ready to support your program's accelerated path to the next milestone.

The company opened the latest Plant 5 early this year to launch its second Bio Campus, bringing total combined capacity up to 784 kL. With the recent launch of our dedicated ADC facility and our fully integrated, end-to-end offerings, we are uniquely positioned to streamline development and manufacturing.

Samsung Biologics will also showcase its competitive strengths in seamless end-to-end CDMO capabilities to support diverse and complex molecules. In the booth, AI-powered operations and digital transformation to optimize bioprocesses will also be featured.

Meetings with existing and potential clients will take place throughout the event to support them in achieving development and manufacturing milestones.